



US007041661B2

(12) **United States Patent**
Zhu et al.

(10) **Patent No.:** **US 7,041,661 B2**
(45) **Date of Patent:** **May 9, 2006**

(54) **USE OF THIAZOLOBENZOHETEROCYCLES FOR TREATING MULTIPLE SCLEROSIS**

(75) Inventors: **Bin Zhu**, Bridgewater, NJ (US); **Joseph Wettstein**, Lebanon, NJ (US); **Margaret A. Petty**, Bridgewater, NJ (US)

(73) Assignee: **Aventis Pharmaceuticals Inc.**, Bridgewater, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 77 days.

(21) Appl. No.: **10/737,634**

(22) Filed: **Dec. 16, 2003**

(65) **Prior Publication Data**

US 2004/0147504 A1 Jul. 29, 2004

Related U.S. Application Data

(60) Provisional application No. 60/434,003, filed on Dec. 17, 2002.

(51) **Int. Cl.**
A61K 31/554 (2006.01)

(52) **U.S. Cl.** **514/211.09**; 514/211.1;
514/211.11; 514/211.12

(58) **Field of Classification Search** 514/211.09,
514/211.1, 211.11, 211.12, 211.01
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,008,280 A 4/1991 Gueremy et al.
6,369,221 B1 * 4/2002 Hardy et al. 540/497

FOREIGN PATENT DOCUMENTS

EP 0374040 3/1993
WO WO99/05147 2/1999
WO WO02100880 12/2002

OTHER PUBLICATIONS

Gilgun-Sherki et al, Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis, *Brain Res.*, Vo. 989, No. 2, Nov., 2003, pp196–204.

Matute C, Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve, *Proceedings of the National Academy of Sciences of USA*, National Academy of Science, Washington, U.S., vol. 95, No. 17, Aug. 1998, pp 10229–10234.

Matute et al, The link between excitotoxic oligodendroglial death and demyelinating diseases, *Trends in Neuroscience*, Apr. 2001, pp 224–230.

Adams, R. A. et al, Multiple Sclerosis and Allied Demyelinating Diseases, *Principles of Neurology*, 6th Edition, 1997, pp 902–927.

Bagetta G et al, Prevention by the NMDA receptor antagonist, MK801 of neuronal loss produced by tetanus toxin in the rat hippocampus, *Br. J. Pharmacology*, vol. 101, 1990, pp 776–780.

Dickenson A. H. et al, Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat, *Neurosc. Letters* vol. 121, 1991, pp 263–266.

Hauser S. L. et al, Multiple Sclerosis and Other Demyelinating Diseases, *Harrison's Principles of Internal Medicine*, 14th Edition, vol. 2, 1998, pp 1409–1419.

Kehne J. H. et al, NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations, *European Journal of Pharmacology*, vol. 193, (1991), pp 283–292.

Lipton, S. A. et al, Synergistic Effects of HIV Coat Protein and NMDA Receptor—Mediated Neurotoxicity, *Neuron*, vol. 7, 1991, pp 111–118.

Mosinger J. L. et al, Blockade of Both NMDA and Non-NMDA Receptors is Required for Optimal Protection Against Ischemic Neuronal Degeneration in the Vivo Adult Mammalian Retina, *Experimental Neurology*, vol. 113, 1991, pp 10–17.

Pujol, R et al, Implication of non-NMDA and NMDA receptors in cochlear ischemia, *Neuro Report*, vol. 3, 1992, pp 200–302.

Reynolds Gavin P, Development in the drug treatment of schizophrenia, *TIPS*, vol. 13, 1992, pp 116–121.

Sluta K. A. et al, An experimental arthritis model in rats: the effects of NMDA and non-NMDA antagonists on aspartate and glutamate release in the dorsal horn, *Neurosc. Letters*, vol. 149, 1993, pp 99–102.

Sorrels T. L. et al, Induction of feeding by 7-chlorokynurenic acid, a strychnine-insensitive glycine binding site antagonist, *Brain Research*, vol. 572, 1992, pp 265–268.

Trullas R et al, Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, *European Journal of Pharmacology*, vol. 185, 1990, pp 1–10.

* cited by examiner


Primary Examiner—Dwayne C. Jones

(74) *Attorney, Agent, or Firm*—Irving Newman

(57) **ABSTRACT**

The invention relates to the use of compound of Formula I in treating patients for inflammatory or neuropathic pain as well as various symptoms of multiple sclerosis

(I)



7 Claims, 2 Drawing Sheets